Cargando…
Modern urology perspectives on prostate cancer biomarkers
INTRODUCTION: Prostate cancer (PCa) is the most common type of cancer among men in Europe. Current recommendations for screening and diagnosis are based on prostate-specific antigen (PSA) measurements and the digital rectal examination (DRE). Both of them are triggers for prostate biopsy. Limited sp...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Polish Urological Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338806/ https://www.ncbi.nlm.nih.gov/pubmed/30680236 http://dx.doi.org/10.5173/ceju.2018.1762 |
_version_ | 1783388498949046272 |
---|---|
author | Szeliski, Kamil Adamowicz, Jan Gastecka, Agata Drewa, Tomasz Pokrywczyńska, Marta |
author_facet | Szeliski, Kamil Adamowicz, Jan Gastecka, Agata Drewa, Tomasz Pokrywczyńska, Marta |
author_sort | Szeliski, Kamil |
collection | PubMed |
description | INTRODUCTION: Prostate cancer (PCa) is the most common type of cancer among men in Europe. Current recommendations for screening and diagnosis are based on prostate-specific antigen (PSA) measurements and the digital rectal examination (DRE). Both of them are triggers for prostate biopsy. Limited specificity of the PSA test brings, however, a need to develop new, better diagnostic tools. Several commercially available variations of the PSA test including: prostate health index (PHI), 4Kscore as well as molecular PCA3 score, have already revealed its value, lowering the number of unnecessary biopsies. MATERIAL AND METHODS: This review summarizes published results of the current most promising, clinically proven and experimentally evaluated PCa biomarkers which have potential for creation of new diagnostic tests. RESULTS: In the last few years new approaches for providing significantly better biomarkers, an alternative to PSA, have been introduced. Modern biomarkers show improvement in being used as not only a diagnosis procedure, but also for staging, evaluating aggressiveness and managing the therapeutic process. The most promising group are molecular markers, among them microRNAs(miRNAs) and long noncoding RNAs (lncRNAs) are most frequent. Their superiority, over standard PSA, in predicting tumor formation in early stages, and clinically non-symptomatic metastases has been noticed. Extracellular vesicles presence in biofluids have brought focus of many research groups, indicating their potential significance. This group of nanoparticles has potential not only in diagnostic and therapy management process, but also as a potential therapeutic target. CONCLUSIONS: Finding better PCa biomarkers, replacing the current PSA measurement, is firmly needed in modern urology practice. |
format | Online Article Text |
id | pubmed-6338806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Polish Urological Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-63388062019-01-24 Modern urology perspectives on prostate cancer biomarkers Szeliski, Kamil Adamowicz, Jan Gastecka, Agata Drewa, Tomasz Pokrywczyńska, Marta Cent European J Urol Review Paper INTRODUCTION: Prostate cancer (PCa) is the most common type of cancer among men in Europe. Current recommendations for screening and diagnosis are based on prostate-specific antigen (PSA) measurements and the digital rectal examination (DRE). Both of them are triggers for prostate biopsy. Limited specificity of the PSA test brings, however, a need to develop new, better diagnostic tools. Several commercially available variations of the PSA test including: prostate health index (PHI), 4Kscore as well as molecular PCA3 score, have already revealed its value, lowering the number of unnecessary biopsies. MATERIAL AND METHODS: This review summarizes published results of the current most promising, clinically proven and experimentally evaluated PCa biomarkers which have potential for creation of new diagnostic tests. RESULTS: In the last few years new approaches for providing significantly better biomarkers, an alternative to PSA, have been introduced. Modern biomarkers show improvement in being used as not only a diagnosis procedure, but also for staging, evaluating aggressiveness and managing the therapeutic process. The most promising group are molecular markers, among them microRNAs(miRNAs) and long noncoding RNAs (lncRNAs) are most frequent. Their superiority, over standard PSA, in predicting tumor formation in early stages, and clinically non-symptomatic metastases has been noticed. Extracellular vesicles presence in biofluids have brought focus of many research groups, indicating their potential significance. This group of nanoparticles has potential not only in diagnostic and therapy management process, but also as a potential therapeutic target. CONCLUSIONS: Finding better PCa biomarkers, replacing the current PSA measurement, is firmly needed in modern urology practice. Polish Urological Association 2018-12-27 2018 /pmc/articles/PMC6338806/ /pubmed/30680236 http://dx.doi.org/10.5173/ceju.2018.1762 Text en Copyright by Polish Urological Association http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Review Paper Szeliski, Kamil Adamowicz, Jan Gastecka, Agata Drewa, Tomasz Pokrywczyńska, Marta Modern urology perspectives on prostate cancer biomarkers |
title | Modern urology perspectives on prostate cancer biomarkers |
title_full | Modern urology perspectives on prostate cancer biomarkers |
title_fullStr | Modern urology perspectives on prostate cancer biomarkers |
title_full_unstemmed | Modern urology perspectives on prostate cancer biomarkers |
title_short | Modern urology perspectives on prostate cancer biomarkers |
title_sort | modern urology perspectives on prostate cancer biomarkers |
topic | Review Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338806/ https://www.ncbi.nlm.nih.gov/pubmed/30680236 http://dx.doi.org/10.5173/ceju.2018.1762 |
work_keys_str_mv | AT szeliskikamil modernurologyperspectivesonprostatecancerbiomarkers AT adamowiczjan modernurologyperspectivesonprostatecancerbiomarkers AT gasteckaagata modernurologyperspectivesonprostatecancerbiomarkers AT drewatomasz modernurologyperspectivesonprostatecancerbiomarkers AT pokrywczynskamarta modernurologyperspectivesonprostatecancerbiomarkers |